An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Carfilzomib (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Pharmacokinetics
- Sponsors Amgen
- 07 Dec 2016 Results of a population pharmacokinetic model analysis and exposure response analysis based on pooled data from PX171-003, PX171-004, PX171-005, PX171-006, PX171-007, ASPIRE, ENDEAVOR, CFZ001 and CFZ002 studies published in the Journal of Clinical Pharmacology.
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 11 Oct 2016 Results assessing safety and pharmacokinetic presented at the 41st European Society for Medical Oncology Congress